Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.

Schettler VJJ, Neumann CL, Peter C, Zimmermann T, Julius U, Hohenstein B, Roeseler E, Heigl F, Grützmacher P, Blume H, Klingel R, Vogt A, Scientific Board of GLAR for the German Apheresis Working Group

Open source

DOI: 10.1007/s11789-019-00094-4
Published: 2019 Apr
Container: Clinical research in cardiology supplements
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s11789-019-00094-4,
  title = {Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.},
  author = {Schettler VJJ and Neumann CL and Peter C and Zimmermann T and Julius U and Hohenstein B and Roeseler E and Heigl F and Grützmacher P and Blume H and Klingel R and Vogt A and Scientific Board of GLAR for the German Apheresis Working Group},
  year = {2019},
  journal = {Clinical research in cardiology supplements},
  doi = {10.1007/s11789-019-00094-4},
  url = {https://doi.org/10.1007/s11789-019-00094-4}
}

RIS

TY  - JOUR
TI  - Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.
AU  - Schettler VJJ
AU  - Neumann CL
AU  - Peter C
AU  - Zimmermann T
AU  - Julius U
AU  - Hohenstein B
AU  - Roeseler E
AU  - Heigl F
AU  - Grützmacher P
AU  - Blume H
AU  - Klingel R
AU  - Vogt A
AU  - Scientific Board of GLAR for the German Apheresis Working Group
PY  - 2019
JO  - Clinical research in cardiology supplements
DO  - 10.1007/s11789-019-00094-4
UR  - https://doi.org/10.1007/s11789-019-00094-4
ER  -

APA

VJJ, S., CL, N., C, P., T, Z., U, J., B, H., E, R., F, H., P, G., H, B., R, K., A, V., & Group, S. B. O. G. F. T. G. A. W. (2019). Lipoprotein apheresis is an optimal therapeutic option to reduce increased Lp(a) levels.. Clinical research in cardiology supplements. https://doi.org/10.1007/s11789-019-00094-4

Source records

pubmed · retrieved 2026-09-26T14:30:43.207Z
europe-pmc · retrieved 2026-09-26T14:30:43.197Z